SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Date of Report: Sepbember 14, 2000
BIORA AB
SE-205 12 Malmo, Sweden
Telephone: (011) 46-40-32-13-33
Indicate by a check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
|X| Form 20-F |_| Form 40-F
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
|_| Yes |X| No
If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b):
Not applicable.
This Form 6-K consists of a press release issued by Biora AB on
September 14, 2000 regarding the German Society of Periodontology
supporting Emdogain.
Press release from Biora AB (publ), September 14, 2000
FOR IMMEDIATE RELEASE
NO 11/00
GERMAN SOCIETY OF PERIODONTOLOGY SUPPORTS EMDOGAIN(R)
MALMO, SWEDEN, SEPTEMBER 14, 2000 - Biora AB (NASDAQ: BIORY, SSE: BIOR)
announced today that the German Society of Periodontology (DGP - Deutsche
Gesellschaft fur Parodontologie) has made the following statement regarding
Emdogain:
"The evidence of histological and controlled clinical studies shows that
the use of enamel matrix proteins, applied to a clean root surface during
flap surgery, is an effective and reliable regenerative method for the
treatment of vertical periodontal bone defects."
- "DGP's statement is very valuable for the acceptance of Emdogain
among periodontists" stated Wolfgang Muller, General Manager of Biora
GmbH. Emdogain, which is the only enamel matrix protein for this kind
of periodontal treatment on the market, is Biora's principal product.
DGP and Biora are also starting a collaboration that aims to improve the
knowledge and proficiency in periodontology in Germany. Organizing courses
in treatment of infrabony defects and providing forums where periodontists
may exchange experiences are examples of running collaboration projects.
- "As a strongly scientific organization, one of DGP's objectives
is to improve the general level of knowledge in the periodontal
field" stated Professor Jorg Meyle, President of DGP. "I feel that
our collaboration projects with Biora serve this objective."
Biora develops manufactures and sells products for the treatment of
periodontal disease and for use in oral surgery. Using its proprietary
technology and expertise, Biora aims to become a world leader in
biology-based products for specialized dental therapy. Biora's American
Depository Shares are listed on the Nasdaq National Market in the US and
Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock
Exchange in Sweden.
This press release may contain certain forward looking statements that
relate to future events or future business and financial performance. Such
statements can only be predictions and the actual events or results may
differ from those discussed. The Company cautions that these statements are
subject to important factors that could cause actual results to differ
materially from those expressed or implied in such forward looking
statements and are more fully discussed in periodic reports filed with
Securities and Exchange Commission.
---------------------------------------------------------------------
FOR FURTHER INFORMATION, PLEASE CONTACT:
Rickard Soderberg, President and CEO of Biora, tel: +46 (0)40 32 13 59
Wolfgang Muller, General Manager of Biora GmbH, tel: +49 (0)61 72 90260
Professor Jorg Meyle, President of DGP, tel: +49 641 99 46 191
Elisabeth Lavers, Biora US-investor relations, +1 203 977 7797
http://www.biora.com
http://www.dgparo.de/service/zahnarzt/main_serv_statement.htm
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
BIORA AB
Dated: September 15, 2000 By: /s/ Anders Agering
-------------------------------
Anders Agering
Chief Financial Officer
